15 results about "Ischemic hypoxia" patented technology

The invention relates to the field of biological medicine, in particular to a si-RNA composition for inducing cardiac fibroblasts to transdifferentiate into endothelial cells and application of the si-RNA composition. The si-RNA composition comprises a si-RNA (Ribonucleic Acid) aiming at a gene Huwe1, a si-RNA aiming at a gene Ltbp3, a si-RNA aiming at a gene Dysf and a si-RNA aiming at a gene Hivep3. The HLDH (Huwe1, Ltbp3, Dysf and Hive3) combined knockout can be used for successfully inducing the transformation of fibroblasts into endothelial cells in an in-vitro ischemia and hypoxia state. A carrier containing shRNA capable of expressing and generating the si-RNA composition is delivered into the heart, so that cardiac fibroblasts undergo transdifferentiation in vivo and participate in angiogenesis, and therefore, increase of fibrosis area and adverse ventricular remodeling after myocardial ischemia are limited through ways such as fibrosis remodeling, the heart function is retained, and myocardial ischemia is improved and repaired.

The utility model discloses a foot protection device of preventing pressure sore, including protection pad, both sides of protection pad are fixedly connected with first buffer pad and second buffer pad respectively, protection pad is equipped with two ankle joint and heel placement opening, first buffer pad is equipped with the U -shaped groove of size adaptation with ankle joint placement opening, protection pad adopts the breathable sponge material, and the inside fills memory cotton, first buffer pad and second buffer pad are all silica gel material, and the surface is provided honeycomb breathable hole, the utility model discloses through the elastic buffer effect of first buffer pad and second buffer pad, the pressure of ankle and heel part is evenly dispersed, avoids the local sustained pressure to lead to ischemia and anoxia, and simultaneously, the breathable material of protection pad and buffer pad can keep the foot dry, reduces the growth of perspiration, reduces the risk of skin damage.

The invention discloses application of salvianolic acid C in preparation of a medicine for preventing and / or treating retinal ischemia hypoxic nerve injury diseases, and relates to the technical field of biological medicines. The invention proposes and verifies for the first time that salvianolic acid C can significantly promote the formation of stress particles in photoreceptor cells under retinal ischemia and hypoxia conditions, and drives the salvianolic acid C to be assembled into a stress particle-mitochondrial micro-region in a mitochondrial adjacent region. The microcell is enriched in DDX3X, LARP1 and other key RNA binding proteins and multiple mitochondrial related proteins to cooperatively maintain mitochondrial membrane potential, inhibit mPTP opening and reduce ROS generation, so that an endogenous apoptosis pathway is inhibited, and the neuroprotective effect on a photoreceptor is achieved. On the basis, the salvianolic acid C is used for preparing the medicine for preventing and / or treating the retinal ischemia hypoxia nerve injury disease, can be used as a nerve protection supplement for existing anti-VEGF treatment, and has innovativeness and application value.

Changes in Reelin levels as well as Reelin signaling alter cognitive function. This can be accomplished by administering a therapeutically effective amount of a repeat fragment of Reelin, or a construct formed from fragment repeats of Reelin to a patient or subject. Changes to Reelin levels can be used to treat various neurodegenerative diseases, neuronal insults, or stroke, such as fragile X syndrome, William's syndrome, Rett syndrome, Down's syndrome, Angelman syndrome, autism, ischemia, hypoxia, Alzheimer's disease, and schizophrenia: Reelin can also be used to alter dendritic spine density, diminished long-term potentiation, and diminished synaptic plasticity and associative learning deficits. Constructs formed from repeat region 3 of full length Reelin and repeat region 5 of full length Reeling or repeat region 3 of full length Reelin and repeat region 6 of full length Reelin have been found particularly useful.

The invention discloses an oxygen supply nutrition delivery micro-fluidic brain organ chip and a preparation method thereof, and belongs to the technical field of biomedical engineering and micro-fluidic organ chips, and the preparation method comprises the following steps: performing oxidative stress treatment on microglial cells, inoculating the microglial cells into an organ culture cavity, and inoculating neurons subjected to hypoxia and ischemia treatment into a peripheral nerve culture cavity; establishing concentration distribution of inflammatory factors or injury related factors through a nutrition mixing matrix and a distribution branch so as to simulate a difference microenvironment between the adjacent end and the far end of a focus; performing time sequence evaluation on the interaction process of microglial cell activation and neuron damage by combining morphological observation and molecular detection; and establishing concentration distribution of inflammatory factors or injury-related factors between the two cavities through a nutrition mixing matrix, and obtaining morphology and molecular readout according to a time sequence of 24-72 hours so as to reproduce the interaction process of microglial cell activation and neuron injury.

1. The name of the design product: pre-adaptation training instrument. 2. The use of the design product: mainly used for preventing cardiovascular and cerebrovascular diseases, enhancing human tolerance to ischemia and hypoxia through physical training. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective drawing.

The embodiment of the invention discloses application of a growth differentiation factor 15 in preparation of a product for treating retinal artery occlusion. In-vitro and in-vivo experiments prove that the GDF15 has the potential of directly treating RAO: in an ischemia and hypoxia R28 cell model, the cell activity can be remarkably improved and apoptosis can be inhibited by the treatment of the recombinant human GDF15 protein. In an RAO mouse model, the GDF15 treatment can promote the survival of retinal ganglion cells and increase the thickness of a nerve fiber layer, and shows a clear eyesight protection effect. The product preferably contains recombinant human GDF15 protein, can inhibit cell death paths caused by ischemia and hypoxia in a targeted manner, and improves pathological changes such as retinal endoedema and tissue atrophy. The invention discloses the direct application of GDF15 as a therapeutic agent in RAO for the first time, provides an experimental basis for developing related drugs, and has important clinical application value in the field of ophthalmic emergency treatment.

The invention discloses an A beta aggregation inhibitor as well as a preparation method and application thereof, and belongs to the technical field of medicines. The structural formula of the aryl imidazole compound is shown in the specification, in-vivo and in-vitro experiments prove that the compound can inhibit the aggregation and fibrosis process of beta-amyloid protein A beta 42, reduce the neurotoxicity of the beta-amyloid protein A beta 42 and play a role in neuroprotection; nematode model experiments prove that the compound can prolong the life of Alzheimer's disease model nematodes, delay disease-related phenotype progression, improve the motor ability of the Alzheimer's disease model nematodes, improve the nerve function state of the Alzheimer's disease model nematodes, increase the survival rate of nerve cells induced by ischemia and hypoxia and reduce cell death. The aryl imidazole compound prepared by the invention can be used as an A beta aggregation inhibitor to be applied to anti-aging and neurodegenerative diseases such as Alzheimer's disease, and has good application prospect and conversion value.

The application discloses an oxygen and nutrient delivery microfluidic brain organ chip and a preparation method thereof, and belongs to the technical field of biomedical engineering and microfluidic organ chip, which comprises the following steps: inoculating microglial cells treated by oxidative stress into an organoid culture cavity, and inoculating neurons treated by ischemia and hypoxia into a peripheral nerve culture cavity; a concentration distribution of inflammatory factors or damage-related factors is established through a nutrient mixing matrix and a distribution branch, so that a difference microenvironment of a lesion adjacent part and a distal end is simulated; a time sequence evaluation on an interaction process of microglial cell activation and neuron damage is performed in combination with morphological observation and molecular detection; the concentration distribution of the inflammatory factors or the damage-related factors is established between the two cavities through the nutrient mixing matrix, morphological and molecular readouts are acquired in a time sequence of 24 to 72 hours, so that the interaction process of the microglial cell activation and the neuron damage is reproduced.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The application discloses application of glycyrrhiza chalcone D in preparation of a drug for treating spontaneous cerebral hemorrhage and belongs to the technical field of biological medicine. The application provides application of glycyrrhiza chalcone D in preparation of a drug for treating and improving prognosis of spontaneous cerebral hemorrhage. Rat experiment results show that glycyrrhiza chalcone D can reduce hematoma of cerebral hemorrhage, reduce death of nerve cells after hemorrhage and reduce levels of inflammatory factors; cell experiment results show that glycyrrhiza chalcone D can be used as an inhibitor of ferroptosis and a COX2 inhibitor, improve ischemia and hypoxia injury of nerve cells after spontaneous cerebral hemorrhage and has a better effect than a commonly used ferroptosis inhibitor Fer-1. The application firstly reports that glycyrrhiza chalcone D is used for treating spontaneous cerebral hemorrhage and improving secondary brain injury, provides a new scheme for treatment of spontaneous cerebral hemorrhage and has a good clinical drug application prospect.

The application discloses a deer source extract and application thereof in preparation of a medicine for treating primary dysmenorrhea, and belongs to the technical field of medicines. The deer horn extract is prepared from deer horn through alkali extraction and acid precipitation, and is purified through molecular weight cut-off, and four P1-P4 deer horn polypeptides with specific amino acid sequences are obtained through further multi-dimensional activity screening. The deer horn polypeptide can play a synergistic effect on multiple targets through regulating uterine tissue prostaglandin balance, inhibiting abnormal contraction of uterine smooth muscle, reducing local inflammatory response, improving ischemia and hypoxia injury, and regulating pain signal transmission, and effectively improves symptoms such as spasm and pain of primary dysmenorrhea. The application also prepares various dosage forms such as tablets and capsules by taking the deer horn extract or the deer horn polypeptide as a main active ingredient, and can meet the needs of different scenes such as acute symptom relief and long-term periodic conditioning, has high safety, good patient compliance, and provides a safe and effective natural intervention scheme for primary dysmenorrhea.

This invention discloses a damage visualization probe for deep brain implantation and its usage method, comprising a probe body, a three-dimensional force sensor, a brain tissue oxygen sensor, a metal sensing electrode, and a control circuit. The three-dimensional force sensor, brain tissue oxygen sensor, and metal sensing electrode are connected to the control circuit. The probe body is a transparent hollow structure, with the three-dimensional force sensor embedded in the probe body's wall interlayer. The brain tissue oxygen sensor is placed in the inner ring of the probe body, and the metal sensing electrode is disposed on the outer wall of the probe body. This invention enables real-time visualization monitoring of parameters such as three-dimensional puncture force and blood oxygenation during surgery, real-time identification of blood vessels and nerve tissue, and continuous postoperative monitoring of neurophysiological function and brain tissue physiological state. This significantly improves surgical safety and accuracy, accurately locates blood vessels, provides early warning of excessive traction force and the risk of ischemia and hypoxia, reduces accidental vascular and nerve damage and postoperative complications, and greatly improves the success rate of surgery.

The invention discloses a USP25 inhibitor AZ1 and application of the USP25 inhibitor AZ1 in treatment of children ischemic hypoxic encephalopathy. In a Lipopolysaccharide (LPS) combined hypoxia induced newborn mouse ischemia and hypoxia model, the dyskinesia of the mouse can be obviously improved by giving the AZ1 to the newborn mouse ischemia and hypoxia model. The USP25 inhibitor AZ1 provided by the invention provides a new drug intervention strategy for treating children ischemic-hypoxic encephalopathy, and has an important clinical application prospect.

The invention belongs to the technical field of cardio-pulmonary resuscitation, and discloses a system and a method for optimizing a cerebral protection mechanism of hypoxic ischemia encephalopathy after cardio-pulmonary resuscitation, which are characterized in that an intracranial pressure monitoring device is used for monitoring the change of intracranial pressure in real time and evaluating the degree of brain injury and the condition of encephaledema; through intracranial pressure monitoring, a treatment scheme can be adjusted in time, and serious complications of cerebral hernia are prevented; meanwhile, the concentration change of oxyhemoglobin and deoxidized hemoglobin in the brain tissue is monitored through the brain oxygen saturation monitor by utilizing a near infrared spectrum technology, and the oxygenation state of the brain tissue is accurately reflected. Brain oxygen saturation monitoring is beneficial for guiding oxygen therapy and ventilation therapy and optimizing oxygen supply and oxygen consumption balance of brain tissue. The optimization system for the cerebral protection mechanism of the ischemic-hypoxic encephalopathy after the cardio-pulmonary resuscitation operation can remarkably reduce the degree of brain injury, promote neural function recovery and reduce the case fatality rate and disability rate of a patient.